Psychiatric Times articleshttps://www.psychiatrictimes.com/newsPsychiatric Times articles© 2026 MJH Life Sciences™ and Psychiatric Times. All rights reserved.Tue, 14 Jul 2026 22:25:53 +00005en-us14447https://www.psychiatrictimes.com/newshttps://www.psychiatrictimes.com/logo.webphttps://www.psychiatrictimes.com/view/americas-250th-birthday-and-the-growth-of-psychiatryhttps://www.psychiatrictimes.com/view/americas-250th-birthday-and-the-growth-of-psychiatry<![CDATA[New treatments, responsible deprescribing, and encouraging 988 gains reshape US mental health on our 250th anniversary.]]>Tue, 14 Jul 2026 14:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/ai-chatbots-and-the-erosion-of-therapeutic-discomforthttps://www.psychiatrictimes.com/view/ai-chatbots-and-the-erosion-of-therapeutic-discomfort<![CDATA[AI chatbots flood mental health care—convenient and validating, yet risky. Learn where they help, where they harm, and why therapists still matter.]]>Tue, 14 Jul 2026 13:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/multidisciplinary-care-and-functional-outcomes-in-schizophrenia-managementhttps://www.psychiatrictimes.com/view/multidisciplinary-care-and-functional-outcomes-in-schizophrenia-management<![CDATA[Discover how coordinated schizophrenia care teams—clinicians, social supports, and peers—improve communication, housing, work, and quality of life.]]>Tue, 14 Jul 2026 12:05:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/vagus-nerve-stimulation-in-difficult-to-treat-depression-when-does-it-work-best-https://www.psychiatrictimes.com/view/vagus-nerve-stimulation-in-difficult-to-treat-depression-when-does-it-work-best-<![CDATA[Where can vagus nerve stimulation fit into treating depression?]]>Tue, 14 Jul 2026 12:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/recognizing-early-warning-signs-of-relapse-in-schizophreniahttps://www.psychiatrictimes.com/view/recognizing-early-warning-signs-of-relapse-in-schizophrenia<![CDATA[Clinicians track relapse risk in schizophrenia by spotting functional decline, paranoia, missed care, and triggers, using family check-ins, brief scales, and labs.]]>Tue, 14 Jul 2026 12:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/vol-43-issue-7-interactivehttps://www.psychiatrictimes.com/view/vol-43-issue-7-interactive<![CDATA[Interactive Issue]]>Mon, 13 Jul 2026 17:14:40 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/vy1706-for-treatment-of-alzheimer-disease-shows-tau-reductions-and-favorable-tolerabilityhttps://www.psychiatrictimes.com/view/vy1706-for-treatment-of-alzheimer-disease-shows-tau-reductions-and-favorable-tolerability<![CDATA[New primate data show IV tau-silencing gene therapy cuts brain tau up to 75% with liver-sparing safety, clearing path for 2026 trial.]]>Mon, 13 Jul 2026 16:32:07 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/beyond-deprescribing-a-formula-for-excellent-clinical-carehttps://www.psychiatrictimes.com/view/beyond-deprescribing-a-formula-for-excellent-clinical-care<![CDATA[A panel of expert psychiatrists define deprescribing as ongoing medication review, guiding safer, personalized psychopharmacology amid polypharmacy, misdiagnosis, and fragmented care.]]>Mon, 13 Jul 2026 14:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/tips-for-leveraging-motivational-interviewing-in-lai-discussions-in-schizophreniahttps://www.psychiatrictimes.com/view/tips-for-leveraging-motivational-interviewing-in-lai-discussions-in-schizophrenia<![CDATA[Motivational interviewing can help psychiatrists address long-acting injectable hesitancy in schizophrenia, according to Gerald Maguire, MD.]]>Sun, 12 Jul 2026 13:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/long-acting-injectables-in-schizophrenia-closing-the-gap-between-evidence-and-practicehttps://www.psychiatrictimes.com/view/long-acting-injectables-in-schizophrenia-closing-the-gap-between-evidence-and-practice<![CDATA[How do you pick an LAI antipsychotic? Molecule first, delivery system second, Jacob Hanaie, PharmD, shared at SoCal Psychiatry.]]>Sat, 11 Jul 2026 20:30:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/comp360-psilocybin-in-treatment-resistant-depression-insights-from-gus-alva-md-dfapahttps://www.psychiatrictimes.com/view/comp360-psilocybin-in-treatment-resistant-depression-insights-from-gus-alva-md-dfapa<![CDATA[Phase 3 COMP360 psilocybin data show lasting TRD relief; experts explain brain-network reset, therapy support, and what approval could mean.]]>Sat, 11 Jul 2026 20:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/psychedelics-orexin-blockers-and-more-inside-the-diverse-new-pipeline-for-depressionhttps://www.psychiatrictimes.com/view/psychedelics-orexin-blockers-and-more-inside-the-diverse-new-pipeline-for-depression<![CDATA[At the Southern California Psychiatry Conference, Jason Kellogg, MD, shares insights into the evolution of the MDD pipeline, with an eye on rapid-acting novel mechanisms. ]]>Sat, 11 Jul 2026 16:30:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/what-clinicians-might-miss-in-adhd-sleep-disorders-comorbidities-and-a-link-to-depressionhttps://www.psychiatrictimes.com/view/what-clinicians-might-miss-in-adhd-sleep-disorders-comorbidities-and-a-link-to-depression<![CDATA[Why sleep checks matter in ADHD: spot apnea, executive dysfunction, and hidden ADHD behind treatment-resistant depression.]]>Sat, 11 Jul 2026 15:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/postpartum-depression-zuranolone-emerging-therapies-and-screening-for-birth-traumahttps://www.psychiatrictimes.com/view/postpartum-depression-zuranolone-emerging-therapies-and-screening-for-birth-trauma<![CDATA[Learn about screening for postpartum depression and available pharmacological treatments. ]]>Sat, 11 Jul 2026 12:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/building-trust-in-schizophrenia-care-how-the-therapeutic-alliance-shapes-outcomeshttps://www.psychiatrictimes.com/view/building-trust-in-schizophrenia-care-how-the-therapeutic-alliance-shapes-outcomes<![CDATA[Gerald A. Maguire, MD, shares his experience and insights on the importance of trust and empathy. ]]>Sat, 11 Jul 2026 11:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/expanding-adhd-pharmacology-pipeline-highlights-with-ann-childress-mdhttps://www.psychiatrictimes.com/view/expanding-adhd-pharmacology-pipeline-highlights-with-ann-childress-md<![CDATA[Explore newly FDA-approved ADHD treatments and late-stage contenders, plus practical guidance on managing sleep disorders with evidence-based behavioral strategies.]]>Fri, 10 Jul 2026 22:30:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/emerging-neuromodulation-and-pharmacotherapy-for-treatment-resistant-depressionhttps://www.psychiatrictimes.com/view/emerging-neuromodulation-and-pharmacotherapy-for-treatment-resistant-depression<![CDATA[Explore rapid TRD breakthroughs: accelerated TMS like SAINT, emerging neuromodulation tools, near-term psychedelic therapies, and why sharper diagnosis improves outcomes.]]>Fri, 10 Jul 2026 18:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/podcast-how-ai-can-help-in-everyday-psychiatry-a-conversation-with-roy-perlis-mdhttps://www.psychiatrictimes.com/view/podcast-how-ai-can-help-in-everyday-psychiatry-a-conversation-with-roy-perlis-md<![CDATA[AI is reshaping psychopharmacology—from TRD prediction to digital phenotyping—while exposing data limits, workflow hurdles, and safety risks in suicide tools.]]>Fri, 10 Jul 2026 13:05:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/consensus-guidelines-for-iv-ketamine-safe-clinical-practicehttps://www.psychiatrictimes.com/view/consensus-guidelines-for-iv-ketamine-safe-clinical-practice<![CDATA[Consensus guidance clarifies IV ketamine dosing, monitoring, staffing and consent to support safer, evidence-based depression treatment.]]>Thu, 09 Jul 2026 14:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/metabolic-mental-health-a-conversation-with-benjamin-i-perry-phd-nicolette-stogios-phd-and-katharine-liang-md-phdhttps://www.psychiatrictimes.com/view/metabolic-mental-health-a-conversation-with-benjamin-i-perry-phd-nicolette-stogios-phd-and-katharine-liang-md-phd<![CDATA[Experts urge metabolic screening across psychiatric diagnoses, spotlighting tailored interventions and tools like PsyMetRiC—while warning risk talks can backfire.]]>Thu, 09 Jul 2026 14:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/podcast-a-transdiagnostic-approach-to-metabolic-health-and-mental-illnesshttps://www.psychiatrictimes.com/view/podcast-a-transdiagnostic-approach-to-metabolic-health-and-mental-illness<![CDATA[Experts explain why every diagnosis needs metabolic screening, how to discuss risk safely, and when to use tools like PsyMetRiC to assess risk.]]>Thu, 09 Jul 2026 14:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/filling-the-gap-between-iv-ketamine-clinical-use-and-evidence-based-standardshttps://www.psychiatrictimes.com/view/filling-the-gap-between-iv-ketamine-clinical-use-and-evidence-based-standards<![CDATA[New Delphi consensus guides off-label IV ketamine for depression, detailing protocols and rapid antisuicidal mechanisms via neuroplasticity and BDNF.]]>Thu, 09 Jul 2026 13:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/developments-in-cannabis-withdrawal-and-addiction-treatmenthttps://www.psychiatrictimes.com/view/developments-in-cannabis-withdrawal-and-addiction-treatment<![CDATA[PP-01 targets CB-1 recovery and dopamine balance, aiming to ease cannabis withdrawal and boost abstinence as a fast-tracked phase 3 trial advances.]]>Wed, 08 Jul 2026 17:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/podcast-discussing-parental-leave-with-patientshttps://www.psychiatrictimes.com/view/podcast-discussing-parental-leave-with-patients<![CDATA[Psychiatrists unpack parental leave anxiety, FMLA gaps, and how smarter time-off planning can reduce postpartum depression and support working families.]]>Wed, 08 Jul 2026 13:05:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/take-home-messages-clinical-confidence-in-transitioning-patients-to-cobenfyhttps://www.psychiatrictimes.com/view/take-home-messages-clinical-confidence-in-transitioning-patients-to-cobenfy<![CDATA[In the final episode, "Take-Home Messages: Clinical Confidence in Transitioning Patients to Cobenfy," David Walling, PhD, explored how these findings add to the evolving evidence base for Cobenfy in schizophrenia, and what questions remain for future research.]]>Wed, 08 Jul 2026 12:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/treating-cannabis-addiction-and-withdrawal-latest-clinical-datahttps://www.psychiatrictimes.com/view/treating-cannabis-addiction-and-withdrawal-latest-clinical-data<![CDATA[New data in cannabis use disorder show investigational drug PP-01 cuts irritability 42% in trials.]]>Tue, 07 Jul 2026 17:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/new-6-month-data-from-second-phase-3-trial-confirms-rapid-effect-of-comp360-for-trdhttps://www.psychiatrictimes.com/view/new-6-month-data-from-second-phase-3-trial-confirms-rapid-effect-of-comp360-for-trd<![CDATA[Phase 3 data show COMP360 psilocybin delivers rapid, lasting relief in treatment-resistant depression; FDA filing advances toward 2027 launch.]]>Tue, 07 Jul 2026 13:32:50 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/balancing-efficacy-tolerability-and-drug-monitoring-in-schizophrenia-treatmenthttps://www.psychiatrictimes.com/view/balancing-efficacy-tolerability-and-drug-monitoring-in-schizophrenia-treatment<![CDATA[Therapeutic drug monitoring clarifies adherence and plasma levels, while long-acting injectables and patches reduce variability and support patient-centered benefit-risk decisions.]]>Tue, 07 Jul 2026 12:05:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/sequencing-and-positioning-antipsychotic-formulations-in-schizophrenia-carehttps://www.psychiatrictimes.com/view/sequencing-and-positioning-antipsychotic-formulations-in-schizophrenia-care<![CDATA[Clinicians weigh oral, LAI and transdermal antipsychotics, urging early use, adherence focus, and side-effect education to optimize outcomes.]]>Tue, 07 Jul 2026 12:00:00 GMTPsychiatric TimesusPsychiatric Times Articleshttps://www.psychiatrictimes.com/view/the-biggest-challenge-in-treating-alzheimer-disease-a-conversation-with-oleg-tcheremissine-mdhttps://www.psychiatrictimes.com/view/the-biggest-challenge-in-treating-alzheimer-disease-a-conversation-with-oleg-tcheremissine-md<![CDATA[Expert explains why Alzheimer disease remains complex, how biomarkers and imaging track amyloid, and what new anti-tau and anti-inflammatory drugs emerge.]]>Mon, 06 Jul 2026 20:00:54 GMTPsychiatric TimesusPsychiatric Times Articles